| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis
|
Nagasaka, Misako
|
|
|
164 |
C |
p. 52-55
|
artikel
|
| 2 |
Contents
|
|
|
|
164 |
C |
p. v-vi
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
164 |
C |
p. iii
|
artikel
|
| 4 |
FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010
|
Debieuvre, Didier
|
|
|
164 |
C |
p. 1-7
|
artikel
|
| 5 |
Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group
|
Armato, Samuel G.
|
|
|
164 |
C |
p. 76-83
|
artikel
|
| 6 |
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery
|
Boch, Tobias
|
|
|
164 |
C |
p. 46-51
|
artikel
|
| 7 |
Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer
|
Kenmotsu, Hirotsugu
|
|
|
164 |
C |
p. 39-45
|
artikel
|
| 8 |
Prognostic implication of tumor spread through air spaces in patients with pathologic N0 lung adenocarcinoma
|
Chen, Shiqi
|
|
|
164 |
C |
p. 33-38
|
artikel
|
| 9 |
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
|
Deboever, Nathaniel
|
|
|
164 |
C |
p. 69-75
|
artikel
|
| 10 |
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
|
Souquet, Pierre-Jean
|
|
|
164 |
C |
p. 84-90
|
artikel
|
| 11 |
Targeting un-MET needs in advanced non-small cell lung cancer
|
Coleman, Niamh
|
|
|
164 |
C |
p. 56-68
|
artikel
|
| 12 |
TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data
|
Jakobsen, Ann-Katrine
|
|
|
164 |
C |
p. 23-32
|
artikel
|
| 13 |
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
|
Rodríguez-Abreu, D.
|
|
|
164 |
C |
p. 8-13
|
artikel
|
| 14 |
Which will carry more weight when CTR > 0.5, solid component size, CTR, tumor size or SUVmax?
|
Zhang, Shaoyuan
|
|
|
164 |
C |
p. 14-22
|
artikel
|
Tijdschrift beschrijving